Drug intelligence / Profile preview

piamprizumab

Development stage: Phase 2
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Piamprizumab is a monoclonal antibody currently undergoing clinical investigation for various cancers. It is administered intravenously and has been studied in combination with other antineoplastic agents. Its precise mechanism of action and specific target are not publicly detailed in the available information.

Brand names: Anniko
Other names: 派安普利单抗

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on piamprizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on piamprizumab.

Explore the full profile